CD8A and neoplasm: IHC analysis of the tumor tissue collected after the treatment protocol (5 weeks) from each cohort showed decreased numbers of MDSCs (Gr-1 positive) and an increased number of CD8+ T cells in the group treated with the combination of VP and anti–PD-L1 treated compared with either of the groups treated with a single drug (Figure 10, C and D).